MGAH22 (margetuximab)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MGAH22 (margetuximab), covering 2020-09-17 to 2020-09-17. Get the full timeline:
Most recent: Clinical Trial Update: Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer [Phase 2]